USFDA–CDSCO-DIA: “Workshop on Global Anti-Infective Drug Development: Challenges and Opportunities”
Antimicrobial resistance (AMR) is one of the major threats to human health in the 21st century, with some bacterial pathogens acquiring resistance to all clinically available antibiotics. Worldwide, infections caused by multi-drug resistant (MDR) bacteria are now a major cause of morbidity & mortality and have markedly enhanced healthcare costs.
The workshop presents a unique opportunity to hear directly from the regulatory and subject matter experts working on Drug Development of Anti-Infectives.
Who should attend?
- Clinical research professionals
- Pharmaceutical Experts working in novel drug development, clinical design and strategy
- Academicians engaged in research
- Hear and learn about the regulatory approach and the science behind the development of anti-infectives through actual case studies shared by the USFDA’s experts from the Department of anti-infective products.
- Explore the possibilities of synergies that can be leveraged in your own drug development programs through this Workshop
Edward M. Cox, MD, MPH • Vice President, Regulatory Affairs
Regfeneron, United States
Sumathi Nambiar, MD, MPH • Senior Director, Child Health and Innovation Leadership Department
Johnson & Johnson, United States
Anand Eswaraiah • Head, Medical and Regulatory Affairs
Syngene International, India
Sudheendra Kulkarni • Medical Product Safety Coordinator
Kristan Callahan • International Relations Specialist
U.S. Food and Drug Administration, India
Anupama Ramkumar • Principal Consultant & CEO
Arkus Research, India
Chandana Pal • Accreditation & Quality Systmes Incharge
Apollo Research & Innovations (ARI), India
Srikanth Tripathy • Director in Charge
National Institute for Research in Tuberculosis, India